.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Fish and Richardson
Johnson and Johnson
Mallinckrodt
Julphar
Covington
McKinsey
Harvard Business School
AstraZeneca

Generated: November 24, 2017

DrugPatentWatch Database Preview

Spectrum Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for SPECTRUM PHARMS, and when can generic versions of SPECTRUM PHARMS drugs launch?

SPECTRUM PHARMS has five approved drugs.

There are six US patents protecting SPECTRUM PHARMS drugs.

There are one hundred and nine patent family members on SPECTRUM PHARMS drugs in twenty-nine countries.

Summary for Spectrum Pharms

International Patents:109
US Patents:6
Tradenames:4
Ingredients:4
NDAs:5
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Spectrum Pharms
FUSILEV
levoleucovorin calcium
SOLUTION;IV (INFUSION)020140-003Apr 29, 2011DISCNYesNo► Subscribe► SubscribeYY ► Subscribe
Spectrum Pharms
EVOMELA
melphalan hydrochloride
POWDER;IV (INFUSION)207155-001Mar 10, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Spectrum Pharms
EVOMELA
melphalan hydrochloride
POWDER;IV (INFUSION)207155-001Mar 10, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Spectrum Pharms
BELEODAQ
belinostat
POWDER;IV (INFUSION)206256-001Jul 3, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Spectrum Pharms
FUSILEV
levoleucovorin calcium
POWDER;IV (INFUSION)020140-001Mar 7, 2008APRXYesYes► Subscribe► SubscribeYY ► Subscribe
Spectrum Pharms
BELEODAQ
belinostat
POWDER;IV (INFUSION)206256-001Jul 3, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Spectrum Pharms
FUSILEV
levoleucovorin calcium
SOLUTION;IV (INFUSION)020140-002Apr 29, 2011DISCNYesNo► Subscribe► SubscribeYY ► Subscribe
Spectrum Pharms
EVOMELA
melphalan hydrochloride
POWDER;IV (INFUSION)207155-001Mar 10, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Spectrum Pharms
EVOMELA
melphalan hydrochloride
POWDER;IV (INFUSION)207155-001Mar 10, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Spectrum Pharms
FUSILEV
levoleucovorin calcium
SOLUTION;IV (INFUSION)020140-002Apr 29, 2011DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SPECTRUM PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
levoleucovorin calcium
Injection50 mg/vial
FUSILEV
12/19/2013
levoleucovorin calcium
Injection10 mg/mL, 17.5 mL vial and 25 mL vial
FUSILEV
10/26/2011

Non-Orange Book Patents for Spectrum Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
4,959,472 Process for preparing substantially pure diastereoisomers of tetrahydrofolic derivatives► Subscribe
7,407,988Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors► Subscribe
7,557,140Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors► Subscribe
9,750,822Sulfoalkyl ether cyclodextrin compositions► Subscribe
7,635,773Sulfoalkyl ether cyclodextrin compositions► Subscribe
7,183,298Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors► Subscribe
6,849,628 Optically active compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Spectrum Pharms Drugs

Country Document Number Estimated Expiration
Japan2008540499► Subscribe
Japan2000136135► Subscribe
Australia2006245495► Subscribe
South Africa8706562► Subscribe
Cyprus1114818► Subscribe
Australia2009241858► Subscribe
Japan5108750► Subscribe
European Patent Office1901729► Subscribe
Spain2445578► Subscribe
World Intellectual Property Organization (WIPO)2009134347► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Accenture
Merck
Cerilliant
Deloitte
Harvard Business School
Boehringer Ingelheim
Moodys
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot